Last reviewed · How we verify
NCT06872684: GUARD
Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)
NA trial testing Surpass Elite with Guardian Flow Diverter System in Aneurysm in 183 participants. Currently enrolling.
31 January 2029
Quick facts
| Lead sponsor | Stryker Neurovascular |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 183 |
| Start date | 20 June 2025 |
| Primary completion | 31 January 2029 |
| Estimated completion | 31 January 2031 |
| Sites | 10 locations across United States |
Drugs / interventions tested
- Surpass Elite with Guardian Flow Diverter System
Conditions studied
- Aneurysm — all drugs for Aneurysm →
- Aneurysm, Intracranial — all drugs for Aneurysm, Intracranial →
Sponsor
Stryker Neurovascular — full company profile →
Who can join
Adults 18 to 80, any sex, with Aneurysm or Aneurysm, Intracranial. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of the Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms with Surpass Elite with GUARDian Flow Diverter (GUARD) trial is to evaluate the safety and efficacy of the Surpass Elite with Guardian Flow Diverter System (FDS) in the treatment of unruptured, wide-neck saccular or fusiform, intracranial aneurysms (IAs) located on the internal carotid artery (ICA) or its branches.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06872684
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Aneurysm
Currently open trials in the same condition.
- NCT06689410 — Multimodal Biocollection Linked to the French Register of Intracranial Aneurysms · NA · recruiting
- NCT06793059 — Evaluation of Flow Diverter Technology Device for Intracranial Aneurysm (SHIELD) · NA · recruiting
- NCT06235619 — Arch Size Study for Anatomical Variations · recruiting
- NCT06189950 — Registration Trial of the Intracranial Visualized Stent for the Wide-necked Intracranial Aneurysms:REBRIDGE · NA · recruiting
- NCT05880680 — SEAL™ME: Saccular Endovascular Aneurysm Lattice System Multicenter Enrollment Global Registry · recruiting
Other Stryker Neurovascular trials
Trials by the same sponsor.
- NCT05544045 — China Surpass Streamline Post-Market Study · terminated
- NCT04380350 — Trenza Embolization Device for Intrasaccular Aneurysm Treatment · active not recruiting
- NCT04195568 — Evaluation of Safety and Effectiveness of Stryker Surpass Evolve™ Flow Diverter System · NA · active not recruiting
- NCT04162483 — Safety and Performance of the Neuroform Atlas™ Stent System · unknown
- NCT04057352 — Citadel Embolization Device Study · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06872684 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Stryker Neurovascular
- Last refreshed: 8 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06872684.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing